---
document_datetime: 2025-12-29 11:07:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ozempic.html
document_name: ozempic.html
version: success
processing_time: 0.1118065
conversion_datetime: 2025-12-31 07:57:17.574873
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ozempic

[RSS](/en/individual-human-medicine.xml/65527)

##### Authorised

This medicine is authorised for use in the European Union

semaglutide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ozempic](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79752)
- [More information on Ozempic](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Ozempic. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ozempic.

For practical information about using Ozempic, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Ozempic and what is it used for?

Ozempic is a diabetes medicine used with diet and exercise to treat adults whose type 2 diabetes is not satisfactorily controlled.

Ozempic can be used on its own in patients who cannot take metformin (another diabetes medicine). It can also be used as an 'add-on' to other diabetes medicines.

Ozempic contains the active substance semaglutide.

## How is Ozempic used?

Ozempic is available as a solution for injection in prefilled pens and can only be obtained with a prescription. It is injected under the skin of the belly, the thigh or the upper arm.

The starting dose of Ozempic is 0.25 mg once a week. After four weeks, this dose should be increased to 0.5 mg. If needed, the dose can be further increased up to a maximum of 1 mg once a week. For further information, see the package leaflet.

## How does Ozempic work?

The active substance in Ozempic, semaglutide, is a 'GLP-1 receptor agonist'. It acts in the same way as GLP-1 (a hormone produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.

## What benefits of Ozempic have been shown in studies?

Studies showed that Ozempic is effective at lowering blood glucose levels and reducing the risk of health complications in patients with type 2 diabetes.

Five studies in over 4,000 patients showed that Ozempic lowered levels of HbA1c (a measure of blood glucose) by between 1.2 and 1.8 percentage points over 10 to 13 months. Ozempic in these studies compared favourably with other treatments, sitagliptin, exenatide and insulin glargine (which led to reductions of 0.55, 0.92, 0.83 percentage points respectively) and placebo (reductions of up to 0.09 percentage points). In addition, the results indicated that treatment with Ozempic was associated with a beneficial fall in body weight.

A further study in over 3,000 diabetes patients at high risk of heart problems showed that overall, heart attack, stroke or death occurred less frequently in patients treated with Ozempic (6.6%) than with placebo (8.9%). When looking at the three 'events' separately, fewer patients taking Ozempic had a heart attack or stroke, but rates of death from heart problems were similar in the two groups.

## What are the risks associated with Ozempic?

The most common side effects with Ozempic (which may affect more than 1 in 10 people) include problems with the digestive system, such as diarrhoea, vomiting and nausea (feeling sick). These are mild or moderate in severity and of short duration. Serious worsening of diabetic retinopathy (damage to the retina, the light sensitive membrane at the back of the eye) is common (it may affect up to 1 in 10 people).

For the full list of all side effects and restrictions with Ozempic, see the package leaflet.

## Why is Ozempic approved?

Ozempic was shown to be effective at controlling blood glucose levels. Treatment with Ozempic also led to weight loss, which is considered beneficial in patients with diabetes. Ozempic was also shown to be effective at reducing the occurrence of serious health complications associated with diabetes such as heart attack and stroke.

Regarding safety, this was considered in line with that of other medicines of the same class. Side effects affecting the digestive system are considered to be manageable. Worsening of diabetic retinopathy has also been observed and will be further investigated.

The European Medicines Agency concluded that the benefits of Ozempic seen in studies outweighed its risk and recommended it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ozempic?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ozempic have been included in the summary of product characteristics and the package leaflet.

## Other information about Ozempic

The European Commission granted a marketing authorisation valid throughout the European Union for Ozempic on 8 February 2018.

The full EPAR for Ozempic can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. For more information about treatment with Ozempic, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Ozempic : EPAR - Summary for the public

English (EN) (76.14 KB - PDF)

**First published:** 21/02/2018

**Last updated:** 21/02/2018

[View](/en/documents/overview/ozempic-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-831)

български (BG) (103.55 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/bg/documents/overview/ozempic-epar-summary-public_bg.pdf)

español (ES) (74.77 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/es/documents/overview/ozempic-epar-summary-public_es.pdf)

čeština (CS) (100.72 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/cs/documents/overview/ozempic-epar-summary-public_cs.pdf)

dansk (DA) (74.17 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/da/documents/overview/ozempic-epar-summary-public_da.pdf)

Deutsch (DE) (75.85 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/de/documents/overview/ozempic-epar-summary-public_de.pdf)

eesti keel (ET) (74.46 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/et/documents/overview/ozempic-epar-summary-public_et.pdf)

ελληνικά (EL) (103.79 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/el/documents/overview/ozempic-epar-summary-public_el.pdf)

français (FR) (78.63 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/fr/documents/overview/ozempic-epar-summary-public_fr.pdf)

hrvatski (HR) (97.8 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/hr/documents/overview/ozempic-epar-summary-public_hr.pdf)

italiano (IT) (75.96 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/it/documents/overview/ozempic-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.31 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/lv/documents/overview/ozempic-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (99.97 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/lt/documents/overview/ozempic-epar-summary-public_lt.pdf)

magyar (HU) (95.07 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/hu/documents/overview/ozempic-epar-summary-public_hu.pdf)

Malti (MT) (104.99 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/mt/documents/overview/ozempic-epar-summary-public_mt.pdf)

Nederlands (NL) (74.39 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/nl/documents/overview/ozempic-epar-summary-public_nl.pdf)

polski (PL) (101.69 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/pl/documents/overview/ozempic-epar-summary-public_pl.pdf)

português (PT) (75.08 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/pt/documents/overview/ozempic-epar-summary-public_pt.pdf)

română (RO) (97.43 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/ro/documents/overview/ozempic-epar-summary-public_ro.pdf)

slovenčina (SK) (100.45 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/sk/documents/overview/ozempic-epar-summary-public_sk.pdf)

slovenščina (SL) (95.11 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/sl/documents/overview/ozempic-epar-summary-public_sl.pdf)

Suomi (FI) (73.98 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/fi/documents/overview/ozempic-epar-summary-public_fi.pdf)

svenska (SV) (74.51 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

21/02/2018

[View](/sv/documents/overview/ozempic-epar-summary-public_sv.pdf)

Ozempic : EPAR - Risk management plan summary

English (EN) (327.8 KB - PDF)

**First published:** 23/02/2022

**Last updated:** 22/06/2022

[View](/en/documents/rmp-summary/ozempic-epar-risk-management-plan-summary_en.pdf)

## Product information

Ozempic : EPAR - Product information

English (EN) (1.15 MB - PDF)

**First published:** 21/02/2018

**Last updated:** 30/09/2025

[View](/en/documents/product-information/ozempic-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-380)

български (BG) (1.39 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/bg/documents/product-information/ozempic-epar-product-information_bg.pdf)

español (ES) (1.22 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/es/documents/product-information/ozempic-epar-product-information_es.pdf)

čeština (CS) (1.38 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/cs/documents/product-information/ozempic-epar-product-information_cs.pdf)

dansk (DA) (1.19 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/da/documents/product-information/ozempic-epar-product-information_da.pdf)

Deutsch (DE) (1.21 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/de/documents/product-information/ozempic-epar-product-information_de.pdf)

eesti keel (ET) (1.14 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/et/documents/product-information/ozempic-epar-product-information_et.pdf)

ελληνικά (EL) (1.9 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/el/documents/product-information/ozempic-epar-product-information_el.pdf)

français (FR) (1.24 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/fr/documents/product-information/ozempic-epar-product-information_fr.pdf)

hrvatski (HR) (1.4 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/hr/documents/product-information/ozempic-epar-product-information_hr.pdf)

íslenska (IS) (1.16 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/is/documents/product-information/ozempic-epar-product-information_is.pdf)

italiano (IT) (1.14 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/it/documents/product-information/ozempic-epar-product-information_it.pdf)

latviešu valoda (LV) (1.35 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/lv/documents/product-information/ozempic-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.34 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/lt/documents/product-information/ozempic-epar-product-information_lt.pdf)

magyar (HU) (1.32 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/hu/documents/product-information/ozempic-epar-product-information_hu.pdf)

Malti (MT) (1.43 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/mt/documents/product-information/ozempic-epar-product-information_mt.pdf)

Nederlands (NL) (1.25 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/nl/documents/product-information/ozempic-epar-product-information_nl.pdf)

norsk (NO) (1.1 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/no/documents/product-information/ozempic-epar-product-information_no.pdf)

polski (PL) (1.47 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/pl/documents/product-information/ozempic-epar-product-information_pl.pdf)

português (PT) (1.17 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/pt/documents/product-information/ozempic-epar-product-information_pt.pdf)

română (RO) (1.37 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/ro/documents/product-information/ozempic-epar-product-information_ro.pdf)

slovenčina (SK) (1.26 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/sk/documents/product-information/ozempic-epar-product-information_sk.pdf)

slovenščina (SL) (1.42 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/sl/documents/product-information/ozempic-epar-product-information_sl.pdf)

Suomi (FI) (1.25 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/fi/documents/product-information/ozempic-epar-product-information_fi.pdf)

svenska (SV) (1.2 MB - PDF)

**First published:**

21/02/2018

**Last updated:**

30/09/2025

[View](/sv/documents/product-information/ozempic-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000287437 25/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ozempic : EPAR - All Authorised presentations

English (EN) (27.95 KB - PDF)

**First published:** 21/02/2018

**Last updated:** 09/07/2025

[View](/en/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-97)

български (BG) (57.66 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/bg/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_bg.pdf)

español (ES) (28.48 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/es/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_es.pdf)

čeština (CS) (56.56 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/cs/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.44 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/da/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (27.32 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/de/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (25.29 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/et/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (56.1 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/el/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_el.pdf)

français (FR) (26.86 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/fr/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (47.64 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/hr/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (26.62 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/is/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_is.pdf)

italiano (IT) (28.42 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/it/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (48.3 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/lv/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (47.48 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/lt/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.23 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/hu/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (50.28 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/mt/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (26.73 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/nl/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (25.04 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/no/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_no.pdf)

polski (PL) (53.18 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/pl/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_pl.pdf)

português (PT) (25.04 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/pt/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_pt.pdf)

română (RO) (53.36 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/ro/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (51.56 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/sk/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (50.73 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/sl/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (25.78 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/fi/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (27.25 KB - PDF)

**First published:**

21/02/2018

**Last updated:**

09/07/2025

[View](/sv/documents/all-authorised-presentations/ozempic-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ozempic Active substance semaglutide International non-proprietary name (INN) or common name semaglutide Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code A10BJ06

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;
- in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

## Authorisation details

EMA product number EMEA/H/C/004174 Marketing authorisation holder

Novo Nordisk A/S

Novo Alle 1

Opinion adopted 09/11/2017 Marketing authorisation issued 08/02/2018 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ozempic : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (165.79 KB - PDF)

**First published:** 13/02/2025

**Last updated:** 30/09/2025

[View](/en/documents/procedural-steps-after/ozempic-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ozempic : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (229.78 KB - PDF)

**First published:** 31/07/2018

**Last updated:** 13/02/2025

[View](/en/documents/procedural-steps-after/ozempic-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Ozempic-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/193347/2023

English (EN) (105.83 KB - PDF)

**First published:** 03/05/2023

[View](/en/documents/scientific-conclusion/ozempic-h-c-psusa-00010671-202205-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Ozempic-H-C-004174-X-0021 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/21773/2022

English (EN) (1.88 MB - PDF)

**First published:** 23/02/2022

[View](/en/documents/variation-report/ozempic-h-c-004174-x-0021-epar-assessment-report-variation_en.pdf)

Ozempic-H-C-PSUSA-00010671-202005 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/114770/2021

English (EN) (150.06 KB - PDF)

**First published:** 28/04/2021

[View](/en/documents/scientific-conclusion/ozempic-h-c-psusa-00010671-202005-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Ozempic-H-C-PSUSA-00010671-201911 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/11051/2021

English (EN) (120.95 KB - PDF)

**First published:** 11/01/2021

[View](/en/documents/scientific-conclusion/ozempic-h-c-psusa-00010671-201911-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Ozempic-H-C-PSUSA-00010671-201905 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/173542/2020

English (EN) (137.62 KB - PDF)

**First published:** 07/04/2020

[View](/en/documents/scientific-conclusion/ozempic-h-c-psusa-00010671-201905-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Ozempic : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/715701/2017

English (EN) (4.44 MB - PDF)

**First published:** 21/02/2018

**Last updated:** 21/02/2018

[View](/en/documents/assessment-report/ozempic-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ozempic

Adopted

Reference Number: EMA/CHMP/726991/2017

English (EN) (73.45 KB - PDF)

**First published:** 15/12/2017

**Last updated:** 15/12/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ozempic_en.pdf)

#### News on Ozempic

[Warning about sharp rise in illegal medicines sold in the EU](/en/news/warning-about-sharp-rise-illegal-medicines-sold-eu) 03/09/2025

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-june-2025) 06/06/2025

[PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy](/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy) 06/06/2025

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-january-2025) 17/01/2025

[EU actions to tackle shortages of GLP-1 receptor agonists](/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists) 26/06/2024

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024) 12/04/2024

[EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens](/en/news/ema-alerts-eu-patients-healthcare-professionals-reports-falsified-ozempic-pens) 18/10/2023

[EMA statement on ongoing review of GLP-1 receptor agonists](/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists) 11/07/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2017) 15/12/2017

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Ozempic : EPAR - Product information - tracked changes

English (EN) (6.93 MB - DOCX)

**First published:** 30/09/2025

[View](/en/documents/product-information-tracked-changes/ozempic-epar-product-information-tracked-changes_en.docx)

#### More information on Ozempic

- [EMEA-001441-PIP01-13-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001441-pip01-13-m03)
- [EMEA-001441-PIP03-17-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001441-pip03-17-m02)
- [Ozempic - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/ozempic)
- [Ozempic - supply shortage](/en/medicines/human/shortages/ozempic)
- [EMEA-001441-PIP05-20 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001441-pip05-20)
- [Ozempic - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/ozempic-0)
- [Ozempic / Victoza - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/ozempic-victoza)
- [Ozempic / Victoza - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/ozempic-victoza-0)
- [DARWIN EU® - Drug Utilisation Study on GLP-1 Receptor Agonists - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000223)

**This page was last updated on** 30/09/2025

## Share this page

[Back to top](#main-content)